This new document builds off of the previously published Best Practices for Consumer Cardiovascular Technology Solutions in January 2022.
February 07, 2024
CTA and ACC Collaborate to Tackle Cardiovascular Disease with Technology
February 7, 2024 — The Consumer Technology Association (CTA) and the American College of Cardiology (ACC) are…
Read More
Findings from the highly-anticipated MOST (Multi-Arm Optimization of Stroke Thrombolysis) trial were presented on the first day of the American Stroke Association’s International Stroke Conference, ISC 2024, being held through Feb. 9 in Phoenix, AZ.
February 07, 2024
Findings from MOST Trial Presented at ISC24: Blood thinners added to clot-busting medication did not improve stroke outcomes
February 7, 2024 — Researchers presenting preliminary late-breaking science presented on the first day of the American…
Read More
During the American Stroke Association’s International Stroke Conference 2024, ISC24, eleven scientists leading the way in stroke research will be recognized for their exceptional professional achievements.
February 07, 2024
American Stroke Association to Honor 11 Leading Scientists at International Stroke Conference ISC 2024
February 7, 2024 — Eleven scientists leading the way in stroke research will be recognized during the American Stroke…
Read More
New phenomapping tool and clinical score could lead to personalized strategies for patients hospitalized with ADHF
February 06, 2024
Machine Learning Informs a New Tool to Guide Treatment for Acute Decompensated Heart Failure
February 6, 2024 — A recent study co-authored by Dr. Matthew Segar, a third-year cardiovascular disease fellow at The…
Read More
ATTRibute-CM results also demonstrated rapid clinical benefit on the composite endpoint of all-cause mortality (ACM) and CVH in patients treated with acoramidis, with time-to-first event Kaplan-Meier curves separating at month 3 and continuing to diverge steadily through Month 30
February 06, 2024
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
February 6, 2024 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and…
Read More
EGF Mapping system aims to improve patient outcomes by enabling precise and personalized ablation strategies
February 06, 2024
Cortex Announces RESOLVE-AF Trial Evaluating Electrographic Flow (EGF) Mapping for use in Atrial Fibrillation Ablation
February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in…
Read More
Latest digital platform provides key advancements to help maintain high signal fidelity while reducing environmental noise
February 02, 2024
GE HealthCare Announces Prucka 3 Digital Amplifier as Next Generation Platform for Electrophysiology Innovation
February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3…
Read More
Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation
February 02, 2024
Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation
February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson &…
Read More
The American College of Cardiology’s Cardiac Oncology Conference, “Advancing the Cardiovascular Care of the Oncology Patient,” will be held at the Heart House in Washington, D.C., from Feb. 9-11, 2024
February 02, 2024
American College of Cardiology (ACC) Program Set for Cardiac Oncology Conference, “Advancing the Cardiovascular Care of the Oncology Patient”
February 2, 2024 — The American College of Cardiology’s Cardiac Oncology Conference, “Advancing the Cardiovascular Care…
Read More
The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.
February 02, 2024
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy Earns FDA Approval for Tricuspid Valve
February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system…
Read More
A new paper in JAMA describes how, despite widespread enthusiasm about AI’s potential and the current use of AI-powered tools, no federal regulations require that AI-powered tools be evaluated for potential harm or benefit to patients
February 01, 2024
Paper Calls for Patient-first Regulation of AI in Healthcare
February 1, 2024 — Ever wonder if the latest and greatest artificial intelligence (AI) tool you read about in the…
Read More
In addressing efficacy, harm, and logistics, the study passes all three of the criteria suggested by the American Heart Association guiding the implementation of polygenic risk scores (PRSs) in cardiovascular care
February 01, 2024
Genomics plc Publishes Clinical Trial Results Demonstrating Successful Integration and Clinical Utility of Integrated Risk Scores Combining Polygenic and Clinical Risk of Cardiovascular Disease in NHS Primary Care
February 1, 2024 —  Genomics plc (Genomics), a healthcare company aiming to transform health through the power of…
Read More
As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, ITN has compiled a snapshot of significant cardiovascular disease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market.
Christine Book
February 01, 2024
American Heart Month Puts Spotlight on Cardiovascular Disease and Stroke Statistics
February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country…
Read More
Here is a look at the most-read content during the month of January on dicardiology.com
By Melinda Taschetta-Millane
February 01, 2024
Top 10: What Viewers Were Reading in January
It is a new year with lots of new content! Here is a look at the most-read content during the month of January on…
Read More
Latest innovation has the potential to reduce anesthesia during minimally invasive procedures
January 31, 2024
New Philips Mini TEE Ultrasound Transducer Helps Improve Cardiac Care for More Patients
January 31, 2024 — Royal Philips, a global leader in health technology, announced that its latest TEE transducer,…
Read More
Outlines methods for interventional cardiologists to identify types of calcified coronary lesions and presents an algorithm to guide the use of calcium modification strategies
January 31, 2024
SCAI Publishes Expert Consensus Statement on Management of Calcified Coronary Lesions Requiring Intervention
January 31, 2024 — Coronary artery calcification is increasing in prevalence, leading to greater risks both during…
Read More
With improvements to the stent graft delivery system enabling a 1 Fr profile reduction on the majority of sizes, the device now offers the most 6 Fr compatible configurations among balloon expandable stent grafts
January 31, 2024
W. L. Gore Receives FDA Approval for Lower Profile Gore Viabahn VBX Balloon Expandable Endoprosthesis
January 31, 2024 — As part of efforts to continuously improve medical solutions for patients with complex vascular…
Read More
The U.S. Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System.
January 31, 2024
Boston Scientific Receives FDA Approval for FARAPULSE Pulsed Field Ablation System
January 31, 2024 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA)…
Read More
Study Reveals Nuances in Pediatric Cardiac Surgery Quality Metrics
January 30, 2024
New Research Finds Volume Alone Does Not Predict Quality Outcomes in Pediatric Cardiac Surgery
January 30, 2024 — A study of pediatric heart surgery centers across the United States has demonstrated that, when it…
Read More
Universal risk predictor for cardiovascular disease, suitable for use in both primary and secondary prevention, would streamline risk assessment
January 30, 2024
Johns Hopkins Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease
January 30, 2024 — Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a single “…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now